Apogee shares have spiked on data showing strong efficacy with its atopic dermatitis drug and the potential for dosing just two to four times a year.

Roche gambled on an all-comer design for trials of its COPD candidate astegolimab, a move that may prove costly as it fails a phase 3 test.